Top in endocrinology: Aspirin cuts diabetes risk; benefits of testosterone therapy limited
Click Here to Manage Email Alerts
The risk for developing diabetes in adults aged 65 years and older was lower in those who received 100 mg of aspirin daily, according to an analysis of the ASPREE study.
A post hoc analysis of the 2018 study found that older adults who take low-dose aspirin daily have a 15% lower risk for developing diabetes compared with placebo. It was the top story in endocrinology last week.
The second top story was about a follow-up survey of men who participated in the T4DM trial. Although more men reported benefits of testosterone undecanoate compared with placebo during the trial, there was no difference in reported benefits between the two groups 5 years after the study concluded.
Read these and more top stories in endocrinology below:
Low-dose aspirin may cut incident diabetes risk for older adults
Low-dose aspirin may help lower the risk for developing diabetes among older adults, according to data that will be presented at the European Association for the Study of Diabetes annual meeting. Read more.
Testosterone not linked to lasting benefit for older men without pathological hypogonadism
Testosterone undecanoate therapy may not confer long-term benefits for men with impaired glucose tolerance and normal testosterone levels, according to a follow-up survey of participants in the T4DM trial. Read more.
Oral acromegaly agent reduces IGF-1 levels below upper limit of normal for most adults
More than 80% of adults with acromegaly achieved an insulin-like growth factor level at or below the upper limit of normal at 36 weeks with an investigational once-daily oral medication, according to topline results from a phase 3 trial. Read more.
Mortality rates after first MI declining in type 2 diabetes, but not type 1 diabetes
All-cause and cardiovascular mortality rates remained flat from 2006 to 2020 for people with type 1 diabetes who had a first-time myocardial infarction, despite mortality rates declining for type 2 diabetes, according to two presenters. Read more.
Top-dose phentermine/topiramate cost-effective after 5 years for adolescents with obesity
Top-dose phentermine/topiramate as an adjunct to lifestyle counseling is the most cost-effective strategy for treating adolescents with obesity over 5 years, according to findings from an economic microsimulation model. Read more.